KRAS and colorectal carcinoma: Recently, published results from a phase I/II study (NCT06500676) that included patients with KRAS G12D-mutant advanced solid tumors (11 with PDAC, 11 with NSCLC, 5 with CRC and 5 others) were used to evaluate the safety, tolerability and efficacy of GFH375.232 The study revealed no dose-limiting toxicities at various dose levels, with good tolerability and promising antitumor activity (ORR: 27.3%, including 3 PR and 4 SD).